SOAT1 and thymoma: JAKi are known to reduce both effector T cells and B cell-mediated immunity, preserving T regulatory cell activity; furthermore, blocking the JAK-STAT pathway could reduce interferon signaling, which was overexpressed in patients with MG, particularly when associated with thymomas [39].